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Michael J. Mack, MD,a and Robert M. Sade, MD,b for the American Association for Thoracic Surgery Ethics Committeec and
The Society of Thoracic Surgeons Standards and Ethics CommitteedThe primary responsibility of specialists in cardiothoracic
surgery is caring for the patient. The sine qua non of effec-
tive patient care is the patient’s trust, manifested as an unwa-
vering belief that our advice and decisions are driven by the
patient’s best interest. We are presented daily with real or po-
tential conflicts of interest, such as remuneration for ordering
tests or performing procedures, enrolling patients in clinical
trials, attending expense-paid, industry-sponsored educa-
tional events, or accepting large or small gifts. To serve
the best interests of our patients and maintain their trust,
we must acknowledge the factors that expose us to risks of
subordinating patients’ interests to the interests of others,
including our own. Some conflicts of interest are inevitable
and some are evitable; we can manage conflicts by avoiding
those we can and resolving those we cannot avoid in favor of
our patients.
Most physicians view themselves as free from bias or
conflicts of interest in carrying out their responsibilities
to patients. At the same time, however, they see other phy-
sicians as being unduly influenced in making patient care
decisions by such external factors as gifts from industry.1,2
We must always be aware of the universal human trait of
self-deception in ourselves. Accepting that we are as subject
to self-deception as our fellow professionals and are con-
fronted with many conflicts of interest every day, we may
serve our patients and profession best with standards for
avoiding or appropriately managing such conflicts.
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About half of the tremendous advances in human well-
being during the past half-century have been brought to us
by drug and device companies’ research and development.3
Moreover, industry’s marketing of new drugs and technolo-
gies should not be underappreciated—without effective mar-
keting, introduction of innovations into clinical use would be
far slower. To deliver state-of-the-art treatment to our pa-
tients most effectively, a collaborative relationship with our
colleagues in industry is necessary and desirable.4 The
many opportunities for collaboration include but are not lim-
ited to development of new drugs and invention of new de-
vices, education regarding existing drugs and devices, and
assistance to surgeons in maintaining current skills and de-
veloping new ones. Cardiothoracic surgeons are eminently
qualified to conduct clinical research trials, to provide inno-
vative ideas and feedback regarding the introduction of new
technologies, and to serve on scientific advisory boards of
medical device and drug companies. Other opportunities
for interaction include development of cutting-edge medical
technologies, improvement of existing products, and educa-
tion of surgeons in the safe and effective use of medical tech-
nologies. Although surgeons are primarily responsible for
ensuring that they acquire the knowledge and skills needed
to use new technologies properly, the companies that develop
and market those technologies are responsible for providing
educational assistance to surgeons when appropriate.
Cardiothoracic surgeons participate in continuing medical
education programs and professional meetings to maintain
and expand the knowledge and skills necessary to provide
optimal patient care. Our academic institutions, training pro-
grams, and professional societies play significant roles in
these activities, and interaction and collaboration with industry
provide a desirable synergy. Collaborative effort often leads to
the best clinical outcomes, obtained through the appropriate
introduction of new technologies as well as research and eval-
uation of existing technologies and techniques. Furthermore,
education regarding new devices and techniques is part of
the Food and Drug Administration’s mandate for introduction
of safe and effective new drugs and devices into clinical med-
icine. Pharmaceutical and medical device manufacturers’
sponsorship of these functions benefits patients, surgeons,
and manufacturers. These relationships, however, can be
abused. The ethical standards enumerated here are intended
to promote appropriate relations between cardiothoracic sur-
geons and our colleagues in industry.
CONFLICT OF INTEREST DEFINED
A conflict of interest occurs when individual’s self-interest
and an obligation diverge. In the clinical setting, the divergencerdiovascular Surgery c Volume 137, Number 5 1047
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first for the patient. A potential conflict of interest is present
when divergence is possible but has not yet occurred. Stated
another way, a conflict of interest exists when professional judg-
ment concerning the well-being of the patient has a reasonable
likelihood of being influenced by other interests of the surgeon,
to the potential detriment of the patient. The surgeon’s interests
may be financial but also may involve fame, notoriety, or pro-
fessional advancement, such as a full partnership in a private
practice or tenure in an academic position.
A conflict of interest does not necessarily result in harm to
a patient; whether the outcome of a conflict is good or bad de-
pends on how it is managed. Most such conflicts can and should
be resolved in favor of benefit to the patient. Perceptions of con-
flicts of interest are of much less concern than poorly managed
conflicts that actually harm patients. A recent study found that
public trust in the medical profession is not eroded by real or
perceived conflicts in patient care, research, or education.5
Examples of relationships in which potential or actual
conflicts of interest may exist follow:
 Membership on scientific advisory boards
 Paid consultancy
 Compensation from employment
 Honoraria and speaker fees
 Paid expert testimony
 Gifts
 Travel
 Meals and hospitality
 Intellectual property rights
 Stock ownership and options
THE AMERICAN ASSOCIATION FOR THORACIC
SURGERYAND THE SOCIETY OF THORACIC
SURGEONS CODES OF ETHICS
The American Association for Thoracic Surgery and the
Society of Thoracic Surgeons have adopted nearly identical
codes of ethics, both of which address a broad range of ethical
concerns affecting cardiothoracic surgery.6,7 The following
ethical standards should be understood and interpreted in the
context of those codes. Both the codes and these standards
necessarily apply specifically to the membership of our cardio-
thoracic societies; however, cardiothoracic residency program
directors would be well advised to require their trainees to fol-
low them as well. In developing this document, similar docu-
ments from several other organizations were consulted.8-11
ETHICAL STANDARDS FOR CARDIOTHORACIC
SURGEONS RELATING TO INDUSTRY*
1. When caring for patients, members must hold the pa-
tient’s welfare paramount.
* In these standards, the words should and must connote lesser and greater degrees of
obligation, respectively. Both terms denote enforceable ethical standards.1048 The Journal of Thoracic and Cardiovascular Su2. Members must prescribe drugs, devices, and treatment
solely on the basis of medical considerations and pa-
tients’ preferences, regardless of any direct or indirect
inducements by industry.
3. Members should inform a patient of any conflicts of
interest arising from their relationships with or investments
in companies that manufacture or supply medications, de-
vices, or therapies to be used for the patient. Any conflict of
interest must be resolved in the best interest of the patient.
4. When faced with a conflict of interest that cannot be eas-
ily resolved, a member should consult with disinterested
colleagues or an institutional ethics committee to deter-
mine if an actual or potential conflict of interest is pres-
ent and if so how to address it.
5. Members should accept no gifts from industry, regard-
less of value. Drug samples intended only for the use
of patients are not considered gifts.
6. Members must accept no direct or indirect financial in-
ducements from industry for using one particular device
or drug rather than another or for switching from one man-
ufacturer’s product to another. Unacceptable inducements
include payment over and above the actual cost of com-
pleting postmarketing surveys of drug or device use.
7. Members who enter into a consulting agreement should
be able to document the following:
 The consulting service was needed.
 The consulting service was actually provided.
 The payment for consultation was not higher than fair
market value.
 No compensation or other incentive was based on the vol-
ume or value of business associated with the agreement.
8. Members should disclose their own or their institution’s
financial relationship with the manufacturer of a drug
or device whenever clinical research or experience with
a particular procedure or device is presented at a meeting
or is published.
9. Members who serve as the principal investigator of any
research project should report fully any influence from
funding sources on designing the project, controlling ac-
cess to the data, preparing a presentation or paper, or con-
trolling timing of presentation or publication.
10. Members should accept no remuneration from industry
to attend any social functions that have no educational
content.
11. Members should not accept any financial support from in-
dustry for attendance at any educational event. Residency
program directors should ensure that industry grants,
which may be extended to residents, are made through
the sponsoring institution, not directly to the resident.
12. Members who are speakers at an industry-supported ed-
ucational event should accept only reasonable honoraria
and reimbursement for travel, meals, and lodging; allrgery c May 2009
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sor, not directly by industry.
13. Members should attend a company-sponsored event only
when the major purpose of the event is education and
training in the proper use of the company’s products;
the only financial considerations should be reimburse-
ment for travel, meals, and lodging. Members should
not accept reimbursement for attending such an educa-
tional event if the event’s location constitutes an induce-
ment that is independent of the event’s educational value.
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